Implication of cancer stem cells in cancer drug development and drug delivery

Journal of Laboratory Automation

Volumn 18, Issue 1, 2013, Pages 6-11

  Chow, Edward Kai Hua ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Cancer stem cells; Drug delivery; Drug development; Nanotechnology

Indexed keywords

CHEMOTHERAPY; CONTROLLED DRUG DELIVERY; CYTOLOGY; DISEASES; DRUG DELIVERY; NANOTECHNOLOGY; RADIOTHERAPY; STEM CELLS; TUMORS;

CANCER STEM CELLS; DRUG DEVELOPMENT; DRUG RESISTANCE; GROWING BODIES; SELF RENEWAL; TUMOR BIOLOGY; TUMOR CELLS; TUMORIGENESIS;

TARGETED DRUG DELIVERY;

ABC TRANSPORTER; ALDEHYDE DEHYDROGENASE; ALDEHYDE DEHYDROGENASE ISOENZYME 1; ALPHA INTERFERON; ANTINEOPLASTIC AGENT; CARBON NANOPARTICLE; DOXORUBICIN; HERMES ANTIGEN; HYALURONIC ACID; IMATINIB; LIPOSOME; MULTIDRUG RESISTANCE PROTEIN; NANODIAMOND; NANOPARTICLE; SINGLE WALLED NANOTUBE; SONIC HEDGEHOG PROTEIN; UNCLASSIFIED DRUG; VISMODEGIB;

BASAL CELL CARCINOMA; CANCER INHIBITION; CANCER STEM CELL; CHRONIC MYELOID LEUKEMIA; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG RESISTANCE; HUMAN; LIPOSOMAL DELIVERY; MEDULLOBLASTOMA; MOLECULARLY TARGETED THERAPY; NANOPHARMACEUTICS; NONHUMAN; PROTO ONCOGENE; REVIEW; SIGNAL TRANSDUCTION; TARGET CELL DESTRUCTION; TUMOR CELL DESTRUCTION;

EID: 84878289809     PISSN: 22110682     EISSN: 22110690     Source Type: Journal    
DOI: 10.1177/2211068212454739     Document Type: Review

References (59)

1. Notta, F.; Mullighan, C. G.; Wang, J. C.; Poeppl, A.; Doulatov, S.; Phillips, L. A.; Ma, J.; Minden, M. D.; Downing, J. R.; Dick, J. E. Evolution of Human BCR-ABL1 Lymphoblastic Leukaemia-Initiating Cells. Nature 2011, 469, 362-367.
2. Reya, T.; Morrison, S. J.; Clarke, M. F.; Weissman, I. L. Stem Cells, Cancer, and Cancer Stem Cells. Nature 2001, 414, 105-111.
3. O'Brien, C. A.; Kreso, A.; Dick, J. E. Cancer Stem Cells in Solid Tumors: An Overview. Semin. Radiat. Oncol. 2009, 19, 71-77.
4. Quintana, E.; Shackleton, M.; Foster, H. R.; Fullen, D. R.; Sabel, M. S.; Johnson, T. M.; Morrison, S. J. Phenotypic Heterogeneity among Tumorigenic Melanoma Cells from Patients That Is Reversible and Not Hierarchically Organized. Cancer Cell 2010, 18, 510-523.
5. Al-Hajj, M.; Wicha, M. S.; Benito-Hernandez, A.; Morrison, S. J.; Clarke, M. F. Prospective Identification of Tumorigenic Breast Cancer Cells. Proc. Natl. Acad. Sci. U. S. A. 2003, 100, 3983-3988.
6. Dylla, S. J.; Beviglia, L.; Park, I. K.; Chartier, C.; Raval, J.; Ngan, L.; Pickell, K.; Aguilar, J.; Lazetic, S.; Smith-Berdan, S.; et al. Colorectal Cancer Stem Cells Are Enriched in Xenogeneic Tumors following Chemotherapy. PLoS One 2008, 3, e2428.
7. Marquardt, J. U.; Raggi, C.; Andersen, J. B.; Seo, D.; Avital, I.; Geller, D.; Lee, Y. H.; Kitade, M.; Holczbauer, A.; Gillen, M. C.; et al. Human Hepatic Cancer Stem Cells Are Characterized by Common Stemness Traits and Diverse Oncogenic Pathways. Hepatology 2011, 54, 1031-1042.
8. Chiba, T.; Kita, K.; Zheng, Y. W.; Yokosuka, O.; Saisho, H.; Iwama, A.; Nakauchi, H.; Taniguchi, H. Side Population Purified from Hepatocellular Carcinoma Cells Harbors Cancer Stem Cell-Like Properties. Hepatology 2006, 44, 240-251.
9. Chaffer, C. L.; Brueckmann, I.; Scheel, C.; Kaestli, A. J.; Wiggins, P. A.; Rodrigues, L. O.; Brooks, M.; Reinhardt, F.; Su, Y.; Polyak, K.; et al. Normal and Neoplastic Nonstem Cells Can Spontaneously Convert to a Stem-Like State. Proc. Natl. Acad. Sci. U. S. A. 2011, 108, 7950-7955.
10. Patrawala, L.; Calhoun, T.; Schneider-Broussard, R.; Zhou, J.; Claypool, K.; Tang, D. G. Side Population Is Enriched in Tumorigenic, Stem-Like Cancer Cells, Whereas ABCG2+ and ABCG2-Cancer Cells Are Similarly Tumorigenic. Cancer Res. 2005, 65, 6207-6219.
11. Chow, E. K.; Fan, L. L.; Chen, X.; Bishop, J. M. Oncogene-Specific Formation of Chemoresistant Murine Hepatic Cancer Stem Cells. Hepatology 2012, Apr 13. [Epub ahead of print]
12. Fairchild, C. R.; Ivy, S. P.; Rushmore, T.; Lee, G.; Koo, P.; Goldsmith, M. E.; Myers, C. E.; Farber, E.; Cowan, K. Carcinogen-Induced mdr Overexpression Is Associated with Xenobiotic Resistance in Rat Preneoplastic Liver Nodules and Hepatocellular Carcinomas. Proc. Natl. Acad. Sci. U. S. A. 1987, 84, 7701-7705.
13. Bello-Reuss, E.; Ernest, S. Expression and Function of P-glycoprotein in Human Mesangial Cells. Am. J. Physiol. 1994, 267, C1351-C1358.
14. Jonker, J. W.; Merino, G.; Musters, S.; van Herwaarden, A. E.; Bolscher, E.; Wagenaar, E.; Mesman, E.; Dale, T. C.; Schinkel, A. H. The Breast Cancer Resistance Protein BCRP (ABCG2) Concentrates Drugs and Carcinogenic Xenotoxins into Milk. Nat. Med. 2005, 11, 127-129.
15. Goodell, M. A.; McKinney-Freeman, S.; Camargo, F. D. Isolation and Characterization of Side Population Cells. Methods Mol. Biol. 2005, 290, 343-352.
16. Goodell, M. A.; Brose, K.; Paradis, G.; Conner, A. S.; Mulligan, R. C. Isolation and Functional Properties of Murine Hematopoietic Stem Cells That Are Replicating In Vivo. J. Exp. Med. 1996, 183, 1797-1806.
17. Ho, M. M.; Ng, A. V.; Lam, S.; Hung, J. Y. Side Population in Human Lung Cancer Cell Lines and Tumors Is Enriched with Stem-Like Cancer Cells. Cancer Res. 2007, 67, 4827-4833.
18. Kondo, T.; Setoguchi, T.; Taga, T. Persistence of a Small Subpopulation of Cancer Stem-Like Cells in the C6 Glioma Cell Line. Proc. Natl. Acad. Sci. U. S. A. 2004, 101, 781-786.
19. Haraguchi, N.; Inoue, H.; Tanaka, F.; Mimori, K.; Utsunomiya, T.; Sasaki, A.; Mori, M. Cancer Stem Cells in Human Gastrointestinal Cancers. Hum. Cell 2006, 19, 24-29.
20. Szotek, P. P.; Pieretti-Vanmarcke, R.; Masiakos, P. T.; Dinulescu, D. M.; Connolly, D.; Foster, R.; Dombkowski, D.; Preffer, F.; Maclaughlin, D. T.; Donahoe, P. K.; et al. Ovarian Cancer Side Population Defines Cells With Stem Cell-Like Characteristics and Mullerian Inhibiting Substance Responsiveness. Proc. Natl. Acad. Sci. U. S. A. 2006, 103, 11154-11159.
21. Sladek, N. E.; Kollander, R.; Sreerama, L.; Kiang, D. T. Cellular Levels of Aldehyde Dehydrogenases (ALDH1A1 and ALDH3A1) as Predictors of Therapeutic Responses to Cyclophosphamide-Based Chemotherapy of Breast Cancer: A Retrospective Study. Rational Individualization of Oxazaphosphorine-Based Cancer Chemotherapeutic Regimens. Cancer Chemother. Pharmacol. 2002, 49, 309-321.
22. Madjd, Z.; Mehrjerdi, A. Z.; Sharifi, A. M.; Molanaei, S.; Shahzadi, S. Z.; Asadi-Lari, M. CD44+ Cancer Cells Express Higher Levels of the Anti-Apoptotic Protein Bcl-2 in Breast Tumours. Cancer Immun. 2009, 9, 4.
23. Ma, S.; Lee, T. K.; Zheng, B. J.; Chan, K. W.; Guan, X. Y. CD133+ HCC Cancer Stem Cells Confer Chemoresistance by Preferential Expression of the Akt/PKB Survival Pathway. Oncogene 2008, 27, 1749-1758.
24. Cammareri, P.; Scopelliti, A.; Todaro, M.; Eterno, V.; Francescangeli, F.; Moyer, M. P.; Agrusa, A.; Dieli, F.; Zeuner, A.; Stassi, G. Aurora-a Is Essential for the Tumorigenic Capacity and Chemoresistance of Colorectal Cancer Stem Cells. Cancer Res. 2010, 70, 4655-4665.
25. Hsu, H. S.; Huang, P. I.; Chang, Y. L.; Tzao, C.; Chen, Y. W.; Shih, H. C.; Hung, S. C.; Chen, Y. C.; Tseng, L. M.; Chiou, S. H. Cucurbitacin I Inhibits Tumorigenic Ability and Enhances Radiochemosensitivity in Nonsmall Cell Lung Cancer-Derived CD133-Positive Cells. Cancer 2011, 117, 2970-2985.
26. Todaro, M.; Alea, M. P.; Di Stefano, A. B.; Cammareri, P.; Vermeulen, L.; Iovino, F.; Tripodo, C.; Russo, A.; Gulotta, G.; Medema, J. P.; et al. Colon Cancer Stem Cells Dictate Tumor Growth and Resist Cell Death by Production of Interleukin-4. Cell Stem Cell 2007, 1, 389-402.
27. Gallmeier, E.; Hermann, P. C.; Mueller, M. T.; Machado, J. G.; Ziesch, A.; De Toni, E. N.; Palagyi, A.; Eisen, C.; Ellwart, J. W.; Rivera, J.; et al. Inhibition of Ataxia Telangiectasia-and Rad3-Related Function Abrogates the In Vitro and In Vivo Tumorigenicity of Human Colon Cancer Cells through Depletion of the CD133(+) Tumor-Initiating Cell Fraction. Stem Cells 2011, 29, 418-429.
28. Angstreich, G. R.; Matsui, W.; Huff, C. A.; Vala, M. S.; Barber, J.; Hawkins, A. L.; Griffin, C. A.; Smith, B. D.; Jones, R. J. Effects of Imatinib and Interferon on Primitive Chronic Myeloid Leukaemia Progenitors. Br. J. Haematol. 2005, 130, 373-381.
29. Preudhomme, C.; Guilhot, J.; Nicolini, F. E.; Guerci-Bresler, A.; Rigal-Huguet, F.; Maloisel, F.; Coiteux, V.; Gardembas, M.; Berthou, C.; Vekhoff, A.; et al. Imatinib plus Peginterferon alfa-2a in Chronic Myeloid Leukemia. N. Engl. J. Med. 2010, 363, 2511-2521.
30. Simonsson, B.; Gedde-Dahl, T.; Markevärn, B.; Remes, K.; Stentoft, J.; Almqvist, A.; Björeman, M.; Flogegård, M.; Koskenvesa, P.; Lindblom, A.; et al. Combination of Pegylated IFN-alpha2b with Imatinib Increases Molecular Response Rates in Patients with Low-or Intermediate-Risk Chronic Myeloid Leukemia. Blood 2011, 118, 3228-3235.
31. Piccirillo, S. G.; Reynolds, B. A.; Zanetti, N.; Lamorte, G.; Binda, E.; Broggi, G.; Brem, H.; Olivi, A.; Dimeco, F.; Vescovi, A. L. Bone Morphogenetic Proteins Inhibit the Tumorigenic Potential of Human Brain Tumour-Initiating Cells. Nature 2006, 444, 761-765.
32. Pires-daSilva, A.; Sommer, R. J. The Evolution of Signalling Pathways in Animal Development. Nat. Rev. Genet. 2003, 4, 39-49.
33. Su, W.; Meng, F.; Huang, L.; Zheng, M.; Liu, W.; Sun, H. Sonic Hedgehog Maintains Survival and Growth of Chronic Myeloid Leukemia Progenitor Cells through beta-Catenin Signaling. Exp. Hematol. 2012, 40, 418-427.
34. Fan, X.; Eberhart, C. G. Medulloblastoma Stem Cells. J. Clin. Oncol. 2008, 26, 2821-2827.
35. Liu, S.; Dontu, G.; Mantle, I. D.; Patel, S.; Ahn, N.; Jackson, K.; Suri, P.; Wicha, M. Hedgehog Signaling and Bmi-1 Regulate Self-Renewal of Normal and Malignant Human Mammary Stem Cells. Cancer Res. 2006, 66, 6063-6071.
36. Li, C.; Heidt, D. G.; Dalerba, P.; Burant, C. F.; Zhang, L.; Adsay, V.; Wicha, M.; Clarke, M. F.; Simeone, D. M. Identification of Pancreatic Cancer Stem Cells. Cancer Res. 2007, 67, 1030-1037.
37. Chen, X.; Lingala, S.; Khoobyari, S.; Nolta, J.; Zern, M. A.; Wu, J. Epithelial Mesenchymal Transition and Hedgehog Signaling Activation Are Associated with Chemoresistance and Invasion of Hepatoma Subpopulations. J. Hepatol. 2011, 55, 838-845.
38. Rudin, C. M.; Hann, C. L.; Laterra, J.; Yauch, R. L.; Callahan, C. A.; Fu, L.; Holcomb, T.; Stinson, J.; Gould, S. E.; Coleman, B.; et al. Treatment of Medulloblastoma with Hedgehog Pathway Inhibitor GDC-0449. N. Engl. J. Med. 2009, 361, 1173-1178.
39. LoRusso, P. M.; Rudin, C. M.; Reddy, J. C.; Tibes, R.; Weiss, G. J.; Borad, M. J.; Hann, C. L.; Brahmer, J. R.; Chang, I.; Darbonne, W. C.; et al. Phase I Trial of Hedgehog Pathway Inhibitor Vismodegib (GDC-0449) in Patients with Refractory, Locally Advanced or Metastatic Solid Tumors. Clin. Cancer Res. 2011, 17, 2502-2511.
40. Zhang, T.; Otevrel, T.; Gao, Z.; Ehrlich, S. M.; Fields, J. Z.; Boman, B. M. Evidence That APC Regulates Survivin Expression: A Possible Mechanism Contributing to the Stem Cell Origin of Colon Cancer. Cancer Res. 2001, 61, 8664-8667.
41. Sherry, M. M.; Reeves, A.; Wu, J. K.; Cochran, B. H. STAT3 Is Required for Proliferation and Maintenance of Multipotency in Glioblastoma Stem Cells. Stem Cells 2009, 27, 2383-2392.
42. Lessard, J.; Sauvageau, G. Bmi-1 Determines the Proliferative Capacity of Normal and Leukaemic Stem Cells. Nature 2003, 423, 255-260.
43. Guzmán-Ramírez, N.; Völler, M.; Wetterwald, A.; Germann, M.; Cross, N. A.; Rentsch, C. A.; Schalken, J.; Thalmann, G. N.; Cecchini, M. G. In Vitro Propagation and Characterization of Neoplastic Stem/Progenitor-Like Cells from Human Prostate Cancer Tissue. Prostate 2009, 69, 1683-1693.
44. Chow, E. K.; Zhang, X. Q.; Chen, M.; Lam, R.; Robinson, E.; Huang, H.; Schaffer, D.; Osawa, E.; Goga, A.; Ho, D. Nanodiamond Therapeutic Delivery Agents Mediate Enhanced Chemoresistant Tumor Treatment. Sci. Transl. Med. 2011, 3, 73ra21.
45. Huang, H.; Pierstorff, E.; Osawa, E.; Ho, D. Active Nanodiamond Hydrogels for Chemotherapeutic Delivery. Nano. Lett. 2007, 7, 3305-3314.
46. Zhang, X. Q.; Chen, M.; Lam, R.; Xu, X.; Osawa, E.; Ho, D. Polymer-Functionalized Nanodiamond Platforms as Vehicles for Gene Delivery. ACS Nano. 2009, 3, 2609-2616.
47. Manus, L. M.; Mastarone, D. J.; Waters, E. A.; Zhang, X. Q.; Schultz-Sikma, E. A.; Macrenaris, K. W.; Ho, D.; Meade, T. J. Gd(III)-nanodiamond Conjugates for MRI Contrast Enhancement. Nano. Lett. 2010, 10, 484-489.
48. Liu, Z.; Chen, K.; Davis, C.; Sherlock, S.; Cao, Q.; Chen, X.; Dai, H. Drug Delivery with Carbon Nanotubes for In Vivo Cancer Treatment. Cancer Res. 2008, 68, 6652-6660.
49. Liu, Y.; Lu, W. L.; Guo, J.; Du, J.; Li, T.; Wu, J. W.; Wang, G. L.; Wang, J. C.; Zhang, X.; Zhang, Q. A Potential Target Associated with Both Cancer and Cancer Stem Cells: A Combination Therapy for Eradication of Breast Cancer Using Vinorelbine Stealthy Liposomes plus Parthenolide Stealthy Liposomes. J. Control. Release 2008, 129, 18-25.
50. Pan, X. Q.; Zheng, X.; Shi, G.; Wang, H.; Ratnam, M.; Lee, R. J. Strategy for the Treatment of Acute Myelogenous Leukemia Based on Folate Receptor beta-Targeted Liposomal Doxorubicin Combined with Receptor Induction Using All-Trans Retinoic Acid. Blood 2002, 100, 594-602.
51. Sugano, M.; Egilmez, N. K.; Yokota, S. J.; Chen, F. A.; Harding, J.; Huang, S. K.; Bankert, R. B. Antibody Targeting of Doxorubicin-Loaded Liposomes Suppresses the Growth and Metastatic Spread of Established Human Lung Tumor Xenografts in Severe Combined Immunodeficient Mice. Cancer Res. 2000, 60, 6942-6949.
52. Dubey, P. K.; Mishra, V.; Jain, S.; Mahor, S.; Vyas, S. P. Liposomes Modified with Cyclic RGD Peptide for Tumor Targeting. J. Drug Target 2004, 12, 257-264.
53. Hallahan, D.; Geng, L.; Qu, S.; Scarfone, C.; Giorgio, T.; Donnelly, E.; Gao, X.; Clanton, J. Integrin-Mediated Targeting of Drug Delivery to Irradiated Tumor Blood Vessels. Cancer Cell 2003, 3, 63-74.
54. Dalerba, P.; Dylla, S. J.; Park, I. K.; Liu, R.; Wang, X.; Cho, R. W.; Hoey, T.; Gurney, A.; Huang, E. H.; Simeone, D. M.; et al. Phenotypic Characterization of Human Colorectal Cancer Stem Cells. Proc. Natl. Acad. Sci. U. S. A. 2007, 104, 10158-10163.
55. Eliaz, R. E.; Szoka, F. C., Jr. Liposome-Encapsulated Doxorubicin Targeted to CD44: A Strategy to Kill CD44-Overexpressing Tumor Cells. Cancer Res. 2001, 61, 2592-2601.
56. Farokhzad, O. C.; Cheng, J.; Teply, B. A.; Sherifi, I.; Jon, S.; Kantoff, P. W.; Richie, J. P.; Langer, R. Targeted Nanoparticle-Aptamer Bioconjugates for Cancer Chemotherapy In Vivo. Proc. Natl. Acad. Sci. U. S. A. 2006, 103, 6315-6320.
57. Farokhzad, O. C.; Jon, S.; Khademhosseini, A.; Tran, T. N.; Lavan, D. A.; Langer, R. Nanoparticle-Aptamer Bioconjugates: A New Approach for Targeting Prostate Cancer Cells. Cancer Res. 2004, 64, 7668-7672.
58. Chau, Y.; Padera, R. F.; Dang, N. M.; Langer, R. Antitumor Efficacy of a Novel Polymer-Peptide-Drug Conjugate in Human Tumor Xenograft Models. Int. J. Cancer 2006, 118, 1519-1526.
59. Longley, D. B.; Johnston, P. G. Molecular Mechanisms of Drug Resistance. J. Pathol. 2005, 205, 275-292.